You can buy or sell TGTX and other stocks, options, ETFs, and crypto commission-free!
TG Therapeutics, Inc. Common Stock, also called TG Therapeutics, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Read More Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Seeking AlphaMay 14
TG Therapeutics: Varied Pipeline With 2 Lead Candidates In Late Stage, Low Cash Position
Due to the poor cash position, I am not considering this a major buy at this time. Despite the cash problem, TGTX could be an interesting stock to consider, post dilution and ahead of catalysts. TG Therapeutics (TGTX) is a developing clinical stage company with 2 lead drugs in 4 phase 3 trials in various indications. Both these are mAbs with unique MoAs in immune-oncology, and we have major catalysts ahead within the next year. The stock is trading near its 52-week low, probably due to the one risk we hav...
Yahoo FinanceMay 11
Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT
Q1 2019 TG Therapeutics Inc Earnings Call NEW YORK May 11, 2019 (Thomson StreetEvents) -- Edited Transcript of TG Therapeutics Inc earnings conference call or presentation Friday, May 10, 2019 at 12:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Jenna Bosco TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communicat...
-$0.43 per share
-$0.43 per share